Craft

Virbac

Stock Price

€349.5

2024-10-29

Market Capitalization

€2.9 B

2024-10-29

Revenue

€1.5 B

FY, 2025

Virbac Summary

Company Summary

Overview
Virbac is a company that manufactures and sells medicines and vaccines to enhance the health of food-producing animals. The company's products comprise a spot-on solution used to treat and prevent flea infestations in dogs and cats, a food supplement for cattle, a vaccine against porcine circovirus, a hydrocortisone aceponate-based corticoid spray, a topical external parasiticide. Its products also include medicines to treat tick, flea, and mosquito infestations in dogs, to treat respiratory diseases in cattle, as well as an ear cleanser, etc. 
Type
Public
Status
Active
Founded
1968
HQ
Carros, FR | view all locations
Website
https://corporate.virbac.com/home.html
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Pierre Madelpuech

    Pierre Madelpuech, Vice-Chairman

    • Sylvie Gueguen

      Sylvie Gueguen, Board Member

      • Solène Madelpuech

        Solène Madelpuech, Board Member

        • Sébastien Huron

          Sébastien Huron, Chief Executive Officer

          LocationsView all

          37 locations detected

          • Carros, Provence-Alpes-Côte d'Azur HQ

            France

            13e rue LID - BP 27

          • Westlake, TX

            United States

            1301 Solana Blvd

          • Canterbury-Bankstown, NSW

            Australia

            361 Horsley Road

          • Wien, Wien

            Austria

            Hildebrandgasse 27

          • Leuven, Vlaams Gewest

            Belgium

            Esperantolaan 4

          • Sao Paulo, SP

            Brazil

            Av. Queiroz Filho, 1560, Vila Hamburguesa

          and 31 others

          Virbac Financials

          Summary Financials

          Revenue (FY, 2025)
          €1.5B
          Gross profit (FY, 2025)
          €1.0B
          Net income (FY, 2025)
          €150.3M
          Cash (FY, 2025)
          €122.5M
          EBIT (FY, 2025)
          €260.0M
          Enterprise value
          $3.1B

          Footer menu